These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
562 related articles for article (PubMed ID: 31555895)
1. The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. Kawakami I; Arai T; Hasegawa M Acta Neuropathol; 2019 Nov; 138(5):751-770. PubMed ID: 31555895 [TBL] [Abstract][Full Text] [Related]
2. Laminar distribution of the pathological changes in sporadic frontotemporal lobar degeneration with transactive response (TAR) DNA-binding protein of 43 kDa (TDP-43) proteinopathy: a quantitative study using polynomial curve fitting. Armstrong RA; Hamilton RL; Mackenzie IR; Hedreen J; Cairns NJ Neuropathol Appl Neurobiol; 2013 Jun; 39(4):335-47. PubMed ID: 22804696 [TBL] [Abstract][Full Text] [Related]
3. TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations. Maekawa S; Leigh PN; King A; Jones E; Steele JC; Bodi I; Shaw CE; Hortobagyi T; Al-Sarraj S Neuropathology; 2009 Dec; 29(6):672-83. PubMed ID: 19496940 [TBL] [Abstract][Full Text] [Related]
4. Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis. Tan RH; Yang Y; Kim WS; Dobson-Stone C; Kwok JB; Kiernan MC; Halliday GM Acta Neuropathol Commun; 2017 Oct; 5(1):76. PubMed ID: 29078806 [TBL] [Abstract][Full Text] [Related]
5. Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Takeda T Neuropathology; 2018 Feb; 38(1):72-81. PubMed ID: 28960544 [TBL] [Abstract][Full Text] [Related]
6. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Riku Y; Watanabe H; Yoshida M; Tatsumi S; Mimuro M; Iwasaki Y; Katsuno M; Iguchi Y; Masuda M; Senda J; Ishigaki S; Udagawa T; Sobue G JAMA Neurol; 2014 Feb; 71(2):172-9. PubMed ID: 24378564 [TBL] [Abstract][Full Text] [Related]
7. [FTLD/ALS as TDP-43 proteinopathies]. Ishihara T; Ariizumi Y; Shiga A; Yokoseki A; Sato T; Toyoshima Y; Kakita A; Takahashi H; Nishizawa M; Onodera O Rinsho Shinkeigaku; 2010 Nov; 50(11):1022-4. PubMed ID: 21921552 [TBL] [Abstract][Full Text] [Related]
8. TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: From pathomechanisms to therapeutic strategies. Ho PC; Hsieh TC; Tsai KJ Ageing Res Rev; 2024 Sep; 100():102441. PubMed ID: 39069095 [TBL] [Abstract][Full Text] [Related]
9. [Clinical and pathological spectrum of TDP-43 associated ALS]. Onodera O; Yokoseki A; Tan CF; Ishihara T; Nishiira Y; Toyoshima Y; Kakita A; Nishizawa M; Takahashi H Rinsho Shinkeigaku; 2010 Nov; 50(11):940-2. PubMed ID: 21921519 [TBL] [Abstract][Full Text] [Related]
10. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Al-Sarraj S; King A; Troakes C; Smith B; Maekawa S; Bodi I; Rogelj B; Al-Chalabi A; Hortobágyi T; Shaw CE Acta Neuropathol; 2011 Dec; 122(6):691-702. PubMed ID: 22101323 [TBL] [Abstract][Full Text] [Related]
11. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. Geser F; Lee VM; Trojanowski JQ Neuropathology; 2010 Apr; 30(2):103-12. PubMed ID: 20102519 [TBL] [Abstract][Full Text] [Related]
12. Drosha inclusions are new components of dipeptide-repeat protein aggregates in FTLD-TDP and ALS C9orf72 expansion cases. Porta S; Kwong LK; Trojanowski JQ; Lee VM J Neuropathol Exp Neurol; 2015 Apr; 74(4):380-7. PubMed ID: 25756586 [TBL] [Abstract][Full Text] [Related]
13. Molecular dissection of TDP-43 proteinopathies. Hasegawa M; Nonaka T; Tsuji H; Tamaoka A; Yamashita M; Kametani F; Yoshida M; Arai T; Akiyama H J Mol Neurosci; 2011 Nov; 45(3):480-5. PubMed ID: 21678031 [TBL] [Abstract][Full Text] [Related]
14. Annexin A11 aggregation in FTLD-TDP type C and related neurodegenerative disease proteinopathies. Robinson JL; Suh E; Xu Y; Hurtig HI; Elman L; McMillan CT; Irwin DJ; Porta S; Van Deerlin VM; Lee EB Acta Neuropathol; 2024 Jun; 147(1):104. PubMed ID: 38896345 [TBL] [Abstract][Full Text] [Related]
15. Ubiquitinated, p62 immunopositive cerebellar cortical neuronal inclusions are evident across the spectrum of TDP-43 proteinopathies but are only rarely additionally immunopositive for phosphorylation-dependent TDP-43. King A; Maekawa S; Bodi I; Troakes C; Al-Sarraj S Neuropathology; 2011 Jun; 31(3):239-49. PubMed ID: 21118398 [TBL] [Abstract][Full Text] [Related]
16. Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype. Mann DMA; Snowden JS Brain Pathol; 2017 Nov; 27(6):723-736. PubMed ID: 28100023 [TBL] [Abstract][Full Text] [Related]
17. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Janssens J; Van Broeckhoven C Hum Mol Genet; 2013 Oct; 22(R1):R77-87. PubMed ID: 23900071 [TBL] [Abstract][Full Text] [Related]
18. Survival in the pre-senile dementia frontotemporal lobar degeneration with TDP-43 proteinopathy: effects of genetic, demographic and neuropathological variables. Armstrong RA Folia Neuropathol; 2016; 54(2):137-48. PubMed ID: 27543771 [TBL] [Abstract][Full Text] [Related]
19. A morphometric study of the spatial patterns of TDP-43 immunoreactive neuronal inclusions in frontotemporal lobar degeneration (FTLD) with progranulin (GRN) mutation. Armstrong RA; Cairns NJ Histol Histopathol; 2011 Feb; 26(2):185-90. PubMed ID: 21154232 [TBL] [Abstract][Full Text] [Related]
20. Disease animal models of TDP-43 proteinopathy and their pre-clinical applications. Liu YC; Chiang PM; Tsai KJ Int J Mol Sci; 2013 Oct; 14(10):20079-111. PubMed ID: 24113586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]